Tracking immune recovery after sepsis: clues to better outcomes
NCT ID NCT01879761
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study looks at how the immune system bounces back in people who survive a severe bloodstream infection caused by Staphylococcus aureus bacteria. Researchers are measuring specific immune markers, like HLA-DR on monocytes, to see if recovery differs between people with and without prior immune problems. The goal is to better understand why some patients develop new infections after sepsis and how to improve their care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which sepsis patients are at higher risk for complications and tailor follow-up care.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to direct changes in patient care, and results may not apply to all sepsis patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
102 people
The number who actually took part.
- Start date
-
Jun 2013
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Hospital inpatients with Staphylococcus aureus bacteremia who are over 18 years old.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * At least one blood culture positive for S. aureus * Patients aged ≥18 years * At least two of four systemic inflammatory response syndrome (SIRS) criteria on the day of positive blood cultures. SIRS criteria are: * Body temperature less than 36°C(96.8°F) or greater than 38°C(100.4°F) * Heart rate greater than 90 beats per minute * Tachypnea (high respiratory rate), with greater than 20 breaths per minute; or, an arterial partial pressure of carbon dioxide less than 32 mmHg * WBC less than 4000 cells/mm³ (4 x 109 cells/L) or greater than 12,000 cells/mm³ (12 x 109 cells/L); or the presence of greater than 10% immature neutrophils (band forms) Exclusion Criteria: * Sequential Organ Failure Assessment (SOFA) score \> 12 on day of positive blood cultures * Survival expected to be \< 7 days from positive blood cultures
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Immune response to sepsis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago Hospital
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.